Journal
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
Volume 50, Issue 1, Pages 90-112Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/00365521.2014.968864
Keywords
Crohn's disease; inflammatory bowel disease; ulcerative colitis
Categories
Funding
- AbbVie
- Boerrhinger
- Cosmo
- Ferring
- Genentech
- GSK
- Novo Nordisk
- NPS
- Pfizer
- Takeda
Ask authors/readers for more resources
Most patients with inflammatory bowel diseases (IBD) are offered conventional medical therapy, because emerging therapies for IBD are regulated by health-care jurisdiction and often limited to academic centres. This review distils current evidence to provide a pragmatic approach to conventional IBD therapy, including aminosalicylates, corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, infliximab and adalimumab. It addresses drug efficacy, safety and salient practice points for optimal and appropriate practice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available